CAS: 1386874-06-1

Samotolisib is a novel drug that has been shown to inhibit tumor growth in vivo. Samotolisib was effective against tumors in a mouse xenograft model, as well as against both skin and bone cancer in mice. The molecular docking analysis suggests that samotolisib binds to the ATP-binding site of the enzyme ribonucleotide reductase (RNR), thereby inhibiting the production of DNA precursors required for protein synthesis. This inhibition leads to apoptosis and necrosis of tumor cells. Samotolisib has also been shown to induce autophagy and apoptosis in cultured human skin cells, suggesting it may have potential for treating skin cancers.

Samotolisib

Samotolisib (LY3023414) inhibits PI3K, DNA-PK, mTOR; tested for solid tumors including breast and colon cancer.